Clinical Trials /

Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy

NCT02004184

Description:

Non-small-cell lung cancer (NSCLC) accounts for a majority (approximately 85%) of lung cancer cases. Patients with localized disease can be cured through surgery, but only 20 % are operable.For the majority of patients with advanced disease, palliative cytotoxic chemotherapy remains the recommended therapy. Chemotherapy prolongs survival and improves quality of life. The recommended first-line therapy is 4-6 courses of a platinum in combination with a third generation compound (e.g. gemcitabine, vinorelbine, docetaxel, pemetrexed, paclitaxel). After first-line therapy, it has been recommended to observe the patients and offer second-line chemotherapy at disease progression. Regimens for second-line therapy include docetaxel or pemetrexed monotherapy. Pemetrexed is less toxic and superior to gemcitabine in non-squamous NSCLC, whereas docetaxel is the recommended second-line therapy in squamous cell carcinoma. The results of the studies of maintenance pemetrexed therapy are encouraging; the observed survival benefit is clinically relevant and relatively large considering the poor survival in patients with advanced NSCLC. Furthermore, pemetrexed appears to be well tolerated. There are, however, several limitations to the studies that have been conducted: Relatively few elderly patients and no PS 2 patients were enrolled - and not all patients on the control-arms received pemetrexed at progression. The overall aim of this study is to investigate whether immediate maintenance pemetrexed therapy prolongs survival compared to observation and pemetrexed therapy at progression in patients with advanced NSCLC. Furthermore, it will be explored whether patients with 'performance status' 2 and elderly ≥ 70 years tolerate and benefit from maintenance therapy; and what characteristics and blood biomarkers are associated with sensitivity and tolerability of such therapy.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Terminated

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy
  • Official Title: Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study

Clinical Trial IDs

  • ORG STUDY ID: 2013/645
  • SECONDARY ID: 2013-001237-41
  • NCT ID: NCT02004184

Conditions

  • Carcinoma, Non-small-cell Lung

Interventions

DrugSynonymsArms
maintenance pemetrexedAlimtamaintenance pemetrexed
pemetrexed at progressionAlimtapemetrexed at progression

Purpose

Non-small-cell lung cancer (NSCLC) accounts for a majority (approximately 85%) of lung cancer cases. Patients with localized disease can be cured through surgery, but only 20 % are operable.For the majority of patients with advanced disease, palliative cytotoxic chemotherapy remains the recommended therapy. Chemotherapy prolongs survival and improves quality of life. The recommended first-line therapy is 4-6 courses of a platinum in combination with a third generation compound (e.g. gemcitabine, vinorelbine, docetaxel, pemetrexed, paclitaxel). After first-line therapy, it has been recommended to observe the patients and offer second-line chemotherapy at disease progression. Regimens for second-line therapy include docetaxel or pemetrexed monotherapy. Pemetrexed is less toxic and superior to gemcitabine in non-squamous NSCLC, whereas docetaxel is the recommended second-line therapy in squamous cell carcinoma. The results of the studies of maintenance pemetrexed therapy are encouraging; the observed survival benefit is clinically relevant and relatively large considering the poor survival in patients with advanced NSCLC. Furthermore, pemetrexed appears to be well tolerated. There are, however, several limitations to the studies that have been conducted: Relatively few elderly patients and no PS 2 patients were enrolled - and not all patients on the control-arms received pemetrexed at progression. The overall aim of this study is to investigate whether immediate maintenance pemetrexed therapy prolongs survival compared to observation and pemetrexed therapy at progression in patients with advanced NSCLC. Furthermore, it will be explored whether patients with 'performance status' 2 and elderly ≥ 70 years tolerate and benefit from maintenance therapy; and what characteristics and blood biomarkers are associated with sensitivity and tolerability of such therapy.

Detailed Description

      In previous studies without maintenance therapy, median overall survival (OS) for performance
      status (PS) 0-1 patients has been approximately 9 months, corresponding to 6 months from
      randomization in this study. We consider an improvement in overall survival of two months to
      be the minimum difference that will lead to routine use of maintenance pemetrexed in Norway.
      To demonstrate an improvement in median overall survival from 6 to 8 months with an α =0.05
      and β =0.20, 198 evaluable patients are required on each arm. We expect a drop-out rate of
      maximum 10 %, and therefore intend to randomize a total of 436 patients (PS 0-1) - of which
      we expect 150 to be 70 years or older.

      Sample size is calculated on PS 0-1 patients only. In addition, PS 2 patients will be
      randomized until the required number of PS 0-1 patients have been accrued. We estimate that a
      total of 100 PS 2 patients will be enrolled - sufficient for hypothesis-generating analyses
      of the benefit of maintenance therapy in elderly and PS 2 patients.

      Based on experience from our previous studies we estimate that approximately 30% of patients
      will not complete or progress during induction chemotherapy; or be ineligible due
      deterioration of PS. Consequently, we need to include approximately 765 patients.
    

Trial Arms

NameTypeDescriptionInterventions
maintenance pemetrexedExperimentalmaintenance pemetrexed immediately after induction chemotherapy
  • maintenance pemetrexed
pemetrexed at progressionActive Comparatorobservation and pemetrexed therapy at disease progression
  • pemetrexed at progression

Eligibility Criteria

        Inclusion Criteria:

          -  Measureable disease according to the RECIST 1.1

          -  Previous radiotherapy is acceptable provided there are measurable, previously not
             irradiated lesions present

          -  Histologically or cytologically confirmed non-squamous non-small cell lung cancer

          -  Stage IIIB ineligible for curative therapy or stage IV disease

          -  ECOG Performance 0-2

          -  Adequate organ function defined as:

               1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 x
                  upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function
                  abnormalities are due to underlying malignancy.

               2. Total serum bilirubin ≤ 1.5 x ULN

               3. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               4. Platelets ≥ 100 x 109/L

               5. Creatinine clearance > 45 ml/min

          -  Able to discontinue NSAIDs and ASA if reduced renal function

          -  All fertile patients should use safe contraception

          -  Written informed consent

        Exclusion Criteria:

          -  prior systemic therapy for advanced non-small-cell lung cancer (including EGFR-TKI).
             Previous chemotherapy (e.g. adjuvant after surgery or for other cancer) is allowed if
             ≥ 3 months since the last course was administered.

          -  activating EGFR-mutation or ALK-translocation detected

          -  serious concomitant systemic disorders (for example active infection, unstable
             cardiovascular disease) that in the opinion of the investigator would compromise the
             patient's ability to complete the study or interfere with the evaluation of the
             efficacy and safety of the study treatment

          -  conditions - medical, social, psychological - which could prevent adequate information
             and follow-up

          -  clinically active cancer other than NSCLC

          -  known hypersensitivity or contraindications for the study drugs (vinorelbine,
             carboplatin, pemetrexed, B12, folate)

          -  pregnant or lactating women
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:overall survival
Time Frame:2 years
Safety Issue:
Description:All patients will be followed until death of any reason - assessed up to 24 months after inclusion in the study.

Secondary Outcome Measures

Measure:progression free survival
Time Frame:2 years
Safety Issue:
Description:From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Measure:Toxicity
Time Frame:2 years
Safety Issue:
Description:All patients will be followed for 2 years (or until 1 month after the end of study therapy if study therapy is discontinued before 2 years after study inclusion).
Measure:Health related quality of life
Time Frame:2 years
Safety Issue:
Description:All patients will be followed until discontinuation of study therapy - up to 24 months after inclusion in the study.

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Norwegian University of Science and Technology

Trial Keywords

  • Pemetrexed
  • drug therapy

Last Updated

December 19, 2017